Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00126607|
Recruitment Status : Terminated (Poor accrual.)
First Posted : August 4, 2005
Last Update Posted : February 28, 2013
|Condition or disease||Intervention/treatment||Phase|
|High-grade Salivary Gland Mucoepidermoid Carcinoma Recurrent Salivary Gland Cancer Salivary Gland Acinic Cell Tumor Salivary Gland Adenocarcinoma Salivary Gland Poorly Differentiated Carcinoma Stage IVA Salivary Gland Cancer Stage IVB Salivary Gland Cancer Stage IVC Salivary Gland Cancer||Biological: trastuzumab Other: laboratory biomarker analysis||Phase 2|
I. To assess response (confirmed and unconfirmed, complete and partial response) in patients with advanced high-grade salivary gland carcinoma treated with trastuzumab.
II. To assess one-year progression-free survival and one-year overall survival for patients treated with this regimen.
III. To assess the toxicities associated with this treatment regimen in this group of patients.
IV. To measure the indicators of C-erb B2 oncoprotein expression and C-erb B2 oncogene amplification and epidermal growth factor receptor expression and explore the relationship between these markers and response, progression-free survival and overall survival in preliminary fashion.
OUTLINE: Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 8 weeks until disease progression and then every 3 months for 1 year and every 6 months until 3 years from study entry.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma|
|Study Start Date :||July 2005|
|Primary Completion Date :||May 2007|
Experimental: Treatment (trastuzumab)
Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Other Names:Other: laboratory biomarker analysis
- Response (confirmed and unconfirmed, complete and partial response) in patients treated with trastuzumab [ Time Frame: Up to 4 years ]A true response probability of 30% or greater would be of interest.
- Progression-free survival [ Time Frame: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 1 year ]
- Overall survival [ Time Frame: Up to 4 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00126607
|United States, Texas|
|Southwest Oncology Group|
|San Antonio, Texas, United States, 78245|
|Principal Investigator:||Madeleine Kane||Southwest Oncology Group|